MARCO promotes cholangiocarcinogenesis by inducing immunosuppression and its targeting reduces tumor growth.

Agirre-Lizaso A, Huici-Izagirre M, O'Rourke CJ, Zhuravleva E, Carpino G, Overi D, Urretabizkaia-Garmendia J, Labiano I, Korosec A, Val B, et al.